DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Novo - 1 Boehringer - 1 Lina Khan - 1 Biden - 1 drugmakers - 1 Joe Biden's - 1 Here's - 1
Top related locs:
U.S Indianapolis North Carolina Trulicity Danish Novo Alcobendas Madrid
Top related orgs:
Amphastar Pharmaceuticals - 3 Novo Nordisk - 2 Federal Trade Commission - 1 FTC - 1 AstraZeneca - 1 Covis Pharma - 1 GlaxoSmithKline - 1 Novartis - 1

Search resuls for: "Amphastar Pharmaceuticals"


4 mentions found


☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
  + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.
Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S
☆ Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
  + stars: | 2023-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85. Shares of Eli Lilly jumped 9% in premarket trading Tuesday. Last month, Eli Lilly filed for Food and Drug Administration approval of the injection for chronic weight management. Eli Lilly said it "has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand." Eli Lilly also reported no sales from its Covid-19 antibody treatments, compared with $129 million in the second quarter of 2022.
Persons: Eli Lilly, Here's, Alimta, Alimta's Organizations: Getty, Refinitiv, Food and Drug, Amphastar Pharmaceuticals, Drug Administration, . Pipeline Locations: U.S
☆ Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap
  + stars: | 2023-08-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +9 min
(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.
Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain
☆ Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion
  + stars: | 2023-04-24 | by ( ) www.reuters.com   time to read: +1 min
April 24 (Reuters) - Amphastar Pharmaceuticals (AMPH.O) will buy Baqsimi from Eli Lilly and Co (LLY.N) in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday. Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal. Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar, or hypoglycemia, in people with diabetes. Launched in 2019, Baqsimi saw worldwide sales worth $139.3 million in 2022, the companies said. Other drugs that are used to treat low blood sugar in diabetes patients include Novo Nordisk's (NOVOb.CO) Zegalogue and GlucaGen and Xeris Pharmaceuticals' Gvoke HypoPen.
0 next >>
Total: 4